BioCentury
ARTICLE | Company News

Otsuka acquiring antibody play Visterra

July 11, 2018 6:50 PM UTC

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday.

The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which is designed to target specific, highly networked epitopes believed to be important in the function of antigens. Otsuka said it is prioritizing platform-based R&D, including antibody development platforms, to make drug discovery more efficient...